Repare therapeutics inc
RPTX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
RPTX 近期報酬表現
-3.13%
Repare therapeutics inc
-0.10%
同產業平均
-1.57%
S&P500
與 RPTX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
ARVN | Arvinas inc | 4 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
TXMD | Therapeuticsmd incorporated | 5 分 | 1 分 | 2 分 | - | 1 分 | |
NRIX | Nurix therapeutics inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
EDIT | Editas medicine inc | 3 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
LSDI | Lucy scientific discovery inc | - | 1 分 | 2 分 | 1 分 | 1 分 |
- ARVN Arvinas inc價值 4 分趨勢 1 分波段 1 分籌碼 3 分股利 1 分查看更多
RPTX 公司資訊
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company's initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.